Masitinib, a c‐kit/PDGF receptor tyrosine kinase inhibitor, improves disease control in severe corticosteroid‐dependent asthmatics
Open accessThe DOI matches its Crossref record.
Abstract
Background: Masitinib is a tyrosine kinase inhibitor targeting stem cell factor receptor (c‐kit) and platelet‐derived growth factor (PDGF) receptor, which are expressed on several cell types including mast cells and bronchial structural cells, respectively. We hypothesized that c‐kit and PDGF receptor inhibition may decrease bronchial inflammation and interfere with airway remodeling, which are crucial features of severe asthma. Objectives: The primary endpoint was the percent change from baseline in oral corticosteroids after 16 weeks of treatment. Change in asthma control (asthma control questionnaire), exacerbation rate, pulmonary function tests, rescue medication requirement and safety were secondary endpoints. Methods: A 16‐week randomized, dose‐ranging (3, 4.5, and 6 mg/kg/day), placebo‐controlled study was undertaken in 44 patients with severe corticosteroid‐dependent asthma who remained poorly controlled despite optimal asthma management. Results: At 16 weeks of treatment, a comparable reduction in oral corticosteroids was achieved with masitinib and placebo (median reduction of 78% and 57% in the masitinib and placebo arms, respectively). Despite this similar reduction, the Asthma Control Questionnaire score was significantly better in the masitinib arm as compared to placebo with a reduction by 0.99 unit at week 16 (P < 0.001) vs 0.43 unit in the placebo arm. Masitinib therapy was associated with more transient skin rash and edema. Conclusions: Masitinib, a c‐kit and PDGF‐receptor tyrosine kinase inhibitor, may represent an innovative avenue of treatment in corticosteroid‐dependent asthma. These preliminary results warrant further long‐term clinical studies in severe asthma (ClinicalTrials.gov Identifier: NCT00842270).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma
Chung, K. F., Wenzel, S. E., Brozek, J. L., Bush, A., Castro, M., Sterk, P. J., Adcock, I. M., Bateman, E. D., Bel, E. H., Bleecker, E. R., et al. (2014) · European Respiratory Journal · doi:10.1183/09031936.00202013 · Cited by 3,926
“020) Better response in those with higher IL-13 levels in sputum Humbert et al, 2009 [324] Severe, CSdependent/44 R, db, pc, p Masitinib (3, 4.”
BackgroundSelf-citationStem Cell Factor Receptor/c-Kit: From Basic Science to Clinical Implications
Lennartsson, J., & Rönnstrand, L. (2012) · Physiological Reviews · doi:10.1152/physrev.00046.2011 · Cited by 825
New developments in mast cell biology
Kalesnikoff, J., & Galli, S. J. (2008) · Nature Immunology · doi:10.1038/ni.f.216 · Cited by 748
A Randomized, Controlled, Phase 2 Study of AMG 317, an IL-4Rα Antagonist, in Patients with Asthma
Corren, J., Busse, W., Meltzer, E. O., Mansfield, L., Bensch, G., Fahrenholz, J., Wenzel, S. E., Chon, Y., Dunn, M., Weng, H. H., et al. (2010) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200909-1448oc · Cited by 299
Masitinib is a broad coronavirus 3CL inhibitor that blocks replication of SARS-CoV-2
Drayman, N., DeMarco, J. K., Jones, K. A., Azizi, S.-A., Froggatt, H. M., Tan, K., Maltseva, N. I., Chen, S., Nicolaescu, V., Dvorkin, S., et al. (2021) · Science · doi:10.1126/science.abg5827 · Cited by 273
Metadata
- Authors
- Humbert, M., De Blay, F., Garcia, G., Prud’homme, A., Leroyer, C., Magnan, A., Tunon‐de‐Lara, J. ‐., Pison, C., Aubier, M., Charpin, D., Vachier, I., Purohit, A., Gineste, P., Bader, T., Moussy, A., Hermine, O., & Chanez, P.
- Venue
- Allergy
- Publisher
- Wiley
- Published
- 2009-07-08
- Volume
- 64
- Issue
- 8
- Pages
- 1194-1201
- ISSN
- 0105-4538 (ISSN-L)
- 1398-9995
- OpenAlex
- W2171835158
- Cited by
- 135
- References
- 0
- FWCI
- 7.48
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Masitinib, a c‐kit/PDGF receptor tyrosine kinase inhibitor, improves disease control in severe corticosteroid‐dependent asthmatics. https://app.cochat.ai/papers/10.1111/j.1398-9995.2009.02122.x
- The paper
- Humbert, M., De Blay, F., Garcia, G., Prud’homme, A., Leroyer, C., Magnan, A., Tunon‐de‐Lara, J. ‐., Pison, C., Aubier, M., Charpin, D., Vachier, I., Purohit, A., Gineste, P., Bader, T., Moussy, A., Hermine, O., & Chanez, P. (2009). Masitinib, a c‐kit/PDGF receptor tyrosine kinase inhibitor, improves disease control in severe corticosteroid‐dependent asthmatics. Allergy. https://doi.org/10.1111/j.1398-9995.2009.02122.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.